189 related articles for article (PubMed ID: 31596080)
1. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Méndez M; Matter H; Defossa E; Kurz M; Lebreton S; Li Z; Lohmann M; Löhn M; Mors H; Podeschwa M; Rackelmann N; Riedel J; Safar P; Thorpe DS; Schäfer M; Weitz D; Breitschopf K
J Med Chem; 2020 Mar; 63(5):2292-2307. PubMed ID: 31596080
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study.
Redij T; Ma J; Li Z; Hua X; Li Z
J Comput Aided Mol Des; 2019 Nov; 33(11):973-981. PubMed ID: 31758355
[TBL] [Abstract][Full Text] [Related]
3. Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.
Willard FS; Wainscott DB; Showalter AD; Stutsman C; Ma W; Cardona GR; Zink RW; Corkins CM; Chen Q; Yumibe N; Agejas J; Cumming GR; Minguez JM; Jiménez A; Mateo AI; Castaño AM; Briere DA; Sloop KW; Bueno AB
J Med Chem; 2021 Mar; 64(6):3439-3448. PubMed ID: 33721487
[TBL] [Abstract][Full Text] [Related]
4. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
Nakane A; Gotoh Y; Ichihara J; Nagata H
Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
[TBL] [Abstract][Full Text] [Related]
5. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
[TBL] [Abstract][Full Text] [Related]
6. An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon-Like Peptide-1 Receptor.
Smelcerovic A; Lazarevic J; Tomovic K; Anastasijevic M; Jukic M; Kocic G; Anderluh M
ChemMedChem; 2019 Mar; 14(5):514-521. PubMed ID: 30609277
[TBL] [Abstract][Full Text] [Related]
7. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.
Wang X; Yun Y; Chen L; Guo S; Niu B; Fang J; Yuan Q; Shen J; Xie X; Wang K
Bioorg Med Chem; 2024 Jun; 107():117761. PubMed ID: 38795571
[TBL] [Abstract][Full Text] [Related]
9. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.
Willard FS; Ho JD; Sloop KW
Adv Pharmacol; 2020; 88():173-191. PubMed ID: 32416867
[TBL] [Abstract][Full Text] [Related]
10. Targeting GLP-1 receptor trafficking to improve agonist efficacy.
Jones B; Buenaventura T; Kanda N; Chabosseau P; Owen BM; Scott R; Goldin R; Angkathunyakul N; Corrêa IR; Bosco D; Johnson PR; Piemonti L; Marchetti P; Shapiro AMJ; Cochran BJ; Hanyaloglu AC; Inoue A; Tan T; Rutter GA; Tomas A; Bloom SR
Nat Commun; 2018 Apr; 9(1):1602. PubMed ID: 29686402
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
[TBL] [Abstract][Full Text] [Related]
12. 2-Aminothiophene derivatives as a new class of positive allosteric modulators of glucagon-like peptide 1 receptor.
Redij T; McKee JA; Do P; Campbell JA; Ma J; Li Z; Miller N; Srikanlaya C; Zhang D; Hua X; Li Z
Chem Biol Drug Des; 2022 Jun; 99(6):857-867. PubMed ID: 35313084
[TBL] [Abstract][Full Text] [Related]
13. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
[TBL] [Abstract][Full Text] [Related]
14. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
Morris LC; Days EL; Turney M; Mi D; Lindsley CW; Weaver CD; Niswender KD
J Biomol Screen; 2014 Jul; 19(6):847-58. PubMed ID: 24525870
[TBL] [Abstract][Full Text] [Related]
15. Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control.
Liu Q; Garg P; Hasdemir B; Wang L; Tuscano E; Sever E; Keane E; Hernandez AGL; Yuan TZ; Kwan E; Lai J; Szot G; Paruthiyil S; Axelrod F; K Sato A
MAbs; 2021; 13(1):1893425. PubMed ID: 33706686
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
[TBL] [Abstract][Full Text] [Related]
17. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity".
Decara JM; Vázquez-Villa H; Brea J; Alonso M; Srivastava RK; Orio L; Alén F; Suárez J; Baixeras E; García-Cárceles J; Escobar-Peña A; Lutz B; Rodríguez R; Codesido E; Garcia-Ladona FJ; Bennett TA; Ballesteros JA; Cruces J; Loza MI; Benhamú B; Rodríguez de Fonseca F; López-Rodríguez ML
J Med Chem; 2022 Apr; 65(7):5449-5461. PubMed ID: 35349261
[TBL] [Abstract][Full Text] [Related]
18. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
[TBL] [Abstract][Full Text] [Related]
19. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
